Outcomes of Fertility Preservation for Female Cancer Patients in a Single Tertiary Center
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To report our experience of fertility preservation (FP) in female cancer patients. Materials and Methods: We retrospectively analyzed the medical records of female who underwent elective oocyte or embryo cryopreservation before cancer treatment between January 2015 and December 2020 at Asan Medical Center. We analyzed the type of cancer, the rate of reuse of cryopreserved oocytes or embryos, and fertility outcomes such as the resumption of menstrua tion or pregnancy. Results: A total of 174 patients underwent 182 oocyte retrieval cycles after controlled ovarian stimulation for oocyte or embryo cryopreservation. The median age of patients was 33.0 (range 19–46) years, and the patients were most unmarried female (65.52%). The majority of patients were diagnosed with breast cancer (78.16%), and the remaining were diagnosed with gastroin testinal (6.33%) and hematologic malignancies (5.75%). The maturation rate of oocyte cryopreservation was 83.33%, and the fertil ization rate of embryo cryopreservation was 72.07%. Of the 57 patients currently not undergoing cancer treatment, 34 resumed menstruating and 19 (33.33%, 19/57) returned to attempt a pregnancy. Among them, five patients succeeded in natural pregnancy. Eleven patients received frozen-thawed embryo transfer, and four patients succeeded in becoming pregnant (36.36%, 4/11). Only 6.3% of patients returned to use their gametes, and 93.7% of gametes are still in storage. Conclusion: FP in cancer patients should be considered before cancer treatment. Through continuous research on oncofertility, it is necessary to consider how to increase the return rate and provide appropriate information to cancer patients of reproduc tive age.
Abstract
Purpose: To report our experience of fertility preservation (FP) in female cancer patients. Materials and Methods: We retrospectively analyzed the medical records of female who underwent elective oocyte or embryo cryopreservation before cancer treatment between January 2015 and December 2020 at Asan Medical Center. We analyzed the type of cancer, the rate of reuse of cryopreserved oocytes or embryos, and fertility outcomes such as the resumption of menstrua tion or pregnancy. Results: A total of 174 patients underwent 182 oocyte retrieval cycles after controlled ovarian stimulation for oocyte or embryo cryopreservation. The median age of patients was 33.0 (range 19–46) years, and the patients were most unmarried female (65.52%). The majority of patients were diagnosed with breast cancer (78.16%), and the remaining were diagnosed with gastroin testinal (6.33%) and hematologic malignancies (5.75%). The maturation rate of oocyte cryopreservation was 83.33%, and the fertil ization rate of embryo cryopreservation was 72.07%. Of the 57 patients currently not undergoing cancer treatment, 34 resumed menstruating and 19 (33.33%, 19/57) returned to attempt a pregnancy. Among them, five patients succeeded in natural pregnancy. Eleven patients received frozen-thawed embryo transfer, and four patients succeeded in becoming pregnant (36.36%, 4/11). Only 6.3% of patients returned to use their gametes, and 93.7% of gametes are still in storage. Conclusion: FP in cancer patients should be considered before cancer treatment. Through continuous research on oncofertility, it is necessary to consider how to increase the return rate and provide appropriate information to cancer patients of reproduc tive age.
참고문헌 (41)
- Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 68, pp.394~424 (2018)
- Massarotti C, "State of the art on oocyte cryopreservation in female cancer patients : a critical review of the literature", Cancer Treat Rev, 57, pp.50~57 (2017)
- Miller KD, "Cancer statistics for adolescents and young adults, 2020", CA Cancer J Clin, 70, pp.443~459 (2020)
- Siegel RL, "Cancer statistics, 2020", CA Cancer J Clin, 70, pp.7~30 (2020)
- ISFP Practice Committee, "Recommendations for fertility preservation in patients with lymphoma, leukemia, and breast cancer", J Assist Reprod Genet, 29, pp.465~468 (2012)
- Cho HW, "Advances in the treatment and prevention of chemotherapy-induced ovarian toxicity", Int J Mol Sci, 21, pp.7792~ (2020)
- Wo JY, "Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients", Int J Radiat Oncol Biol Phys, 73, pp.1304~1312 (2009)
- Baber RJ, "Primary ovarian insufficiency", Curr Obstet Gynecol Rep, 3, pp.223~231 (2014)
- Gargus E, "Management of primary ovarian insufficiency symptoms in survivors of childhood and adolescent cancer", J Natl Compr Canc Netw, 16, pp.1137~1149 (2018)
- Han HS, "Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer", Breast Cancer Res Treat, 115, pp.335~342 (2009)
- Sullivan SD, "Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause", Fertil Steril, 106, pp.1588~1599 (2016)
- 강미주, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2020", Cancer Research and Treatment, 55(2), pp.385~399 (2023), 대한암학회[DOI]
- 정규원, "Prediction of Cancer Incidence and Mortality in Korea, 2023", Cancer Research and Treatment, 55(2), pp.400~407 (2023), 대한암학회[DOI]
- 강상율, "Breast Cancer Statistics in Korea, 2018", Journal of Breast Cancer, 24(2), pp.123~137 (2021), 한국유방암학회[DOI]
- Kim J, "Fertility preservation during cancer treatment : the Korean society for fertility preservation clinical guidelines", Clin Exp Reprod Med, 44, pp.171~174 (2017)
- Oktay K, "Fertility preservation in patients with cancer : ASCO clinical practice guideline update summary", J Oncol Pract, 14, pp.381~385 (2018)
- Practice Committee of the American Society for Reproductive Medicine, "Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy : a committee opinion", Fertil Steril, 112, pp.1022~1033 (2019)
- Reeta Mahey, "Knowledge and awareness about fertility preservation among female patients with cancer : a cross-sectional study", Obstetrics & Gynecology Science, 63(4), pp.480~489 (2020), 대한산부인과학회[DOI]
- Chehin MB, "Knowledge regarding fertility preservation in cancer patients : a population-based survey among Brazilian people during the Pink October awareness event", JBRA Assist Reprod, 21, pp.84~88 (2017)
- Adams E, "Fertility preservation in cancer survivors : a national survey of oncologists' current knowledge, practice and attitudes", Br J Cancer, 108, pp.1602~1615 (2013)
- Vesali S, "Little information about fertility preservation is provided for cancer patients : a survey of oncologists’ knowledge, attitude and current practice", Eur J Cancer Care(Engl), 28, pp.e12947~ (2019)
- Zhang H, "The knowledge, attitude, and self-reported behaviors of oncology physicians regarding fertility preservation in adult cancer patients", J Cancer Educ, 35, pp.1119~1127 (2020)
- Chung JP, "Evaluation of the awareness of, attitude to, and knowledge about fertility preservation in cancer patients among clinical practitioners in Hong Kong", Hong Kong Med J, 23, pp.556~561 (2017)
- Specchia C, "Oocyte cryopreservation in oncological patients:eighteen years experience of a tertiary care referral center", Front Endocrinol(Lausanne), 10, pp.600~ (2019)
- Choi YJ, "The experience of fertility preservation in a single tertiary center in Korea", Front Endocrinol(Lausanne), 13, pp.845051~ (2022)
- Coulam CB, "Intravenous immunoglobulin for treatment of recurrent pregnancy loss", Am J Reprod Immunol, 34, pp.333~337 (1995)
- Arecco L, "Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer : a systematic review and meta-analysis", Hum Reprod, 37, pp.954~968 (2022)
- Marklund A, "Reproductive outcomes after breast cancer in women with vs without fertility preservation", JAMA Oncol, 7, pp.86~91 (2021)
- ESHRE Guideline Group on Female Fertility Preservation, "ESHRE guideline : female fertility preservation", Hum Reprod Open, 2020, pp.hoaa052~ (2020)
- Ethics Committee of the American Society for Reproductive Medicine, "Fertility preservation and reproduction in patients facing gonadotoxic therapies : an Ethics Committee opinion", Fertil Steril, 110, pp.380~386 (2018)
- Martinez-Ibarra NA, "Oncofertility and fertility preservation in cancer patients across the twitterverse", Front Endocrinol(Lausanne), 13, pp.926668~ (2022)
- Melan K, "Fertility preservation healthcare circuit and networks in cancer patients worldwide : what are the issues?", BMC Cancer, 18, pp.192~ (2018)
- von Wolff M, "Fertility-preservation counselling and treatment for medical reasons : data from a multinational network of over 5000 women", Reprod Biomed Online, 31, pp.605~612 (2015)
- Sokolova I, "P-479 oocyte morphology in cancer patients undergoing fertility preservation", Hum Reprod, 37(Supplement 1) (2022)
- Fabiani C, "Oocyte quality assessment in breast cancer: implications for fertility preservation", Cancers(Basel), 14, pp.5718~ (2022)
- Kim SW, "Impact of BRCA mutations and hormone receptor status on reproductive potential in breast cancer patients undergoing fertility preservation", Gynecol Endocrinol, 38, pp.227~230 (2022)
- Moravek MB, "Long-term outcomes in cancer patients who did or did not pursue fertility preservation", Fertil Steril, 109, pp.349~355 (2018)
- Dolmans MM, "Utilization rates and results of long-term embryo cryopreservation before gonadotoxic treatment", J Assist Reprod Genet, 32, pp.1233~1237 (2015)
- Levi-Setti PE, "Delayed childbearing and female ageing impair assisted reproductive technology outcome in survivors of male haematological cancers", J Assist Reprod Genet, 35, pp.2049~2056 (2018)
- Immediata V, "Why are they not coming back? A single-center follow-up study on oncological women oocyte’s storing for fertility preservation", Front Endocrinol (Lausanne), 13, pp.1054123~ (2022)
- Yang IJ, "Usage and cost-effectiveness of elective oocyte freezing : a retrospective observational study", Reprod Biol Endocrinol, 20, pp.123~ (2022)